柳叶刀感染病委员会:抗菌药物耐药六年回顾
本文回顾了自2013年柳叶刀感染病委员会描述全球抗菌药物耐药状况以来的进展。期间公众认知提升,各国采取行动并启动全球倡议,包括2016年联合国大会高级别会议决议。进展包括印度禁止不合理药物组合、承诺禁止粘菌素作为动物生长促进剂、改善医院感染控制及加强抗菌药物管理。但努力零散且国家间不均衡,持续资金和统一监测目标仍迫切需求,除少数领先国家外,耐药问题未获国家领导人持续关注。
要点
- 全球抗菌药物耐药认知提升,但行动零散且国家间不均衡。
- 部分国家采取具体措施,如印度禁止不合理药物组合。
- 持续资金和统一监测目标仍是迫切需求。
核心结论
- 抗菌药物耐药需持续资金和全球统一监测目标,目前除少数国家外未获持续关注。
研究设计与样本
- 本文为柳叶刀感染病委员会对2013年报告后6年进展的回顾性综述。
主要发现
- 公众认知提升带来国家行动和全球倡议,包括2016年联合国大会决议。
- 进展包括印度禁止不合理药物组合、承诺禁止粘菌素作为动物生长促进剂、改善感染控制及抗菌药物管理。
- 资金已动员,新抗生素开发监管障碍已放宽。
- 努力零散且国家间不均衡。
临床怎么用
- 临床医生应关注抗菌药物管理及医院感染控制措施的落实。
局限性
- 进展零散且国家间不均衡,除少数国家外未获持续关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2013, a Lancet Infectious Diseases Commission described the state of antimicrobial resistance worldwide. Since then, greater awareness of the public health ramifications of antimicrobial resistance has led to national actions and global initiatives, including a resolution at the high-level meeting of the UN General Assembly in 2016. Progress in addressing this issue has ranged from a ban on irrational drug combinations in India to commitments to ban colistin as a growth promoter in animals, improve hospital infection control, and implement better antimicrobial stewardship. Funds have been mobilised, and regulatory barriers to new antibiotic development have been relaxed. These efforts have been episodic and uneven across countries, however. Sustained funding for antimicrobial resistance and globally harmonised targets to monitor progress are still urgently needed. Except for in a few leading countries, antimicrobial resistance has not captured the sustained focus of national leaders and country-level actors, including care providers.
引用
- Laxminarayan R, Van Boeckel T, Frost I, et al. The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. Lancet Infect Dis. 2020. PMID: 32059790. doi:10.1016/S1473-3099(20)30003-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。